ABACAVIR/LAMIVUDINE LAPL 600/300 abacavir (as hydrochloride) 600 mg and lamivudine 300 mg film-coated tablet blister pack

Valsts: Austrālija

Valoda: angļu

Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)

Aktīvā sastāvdaļa:

lamivudine, Quantity: 300 mg; abacavir hydrochloride monohydrate, Quantity: 714.162 mg (Equivalent: abacavir, Qty 600 mg)

Pieejams no:

Lupin Australia Pty Limited

SNN (starptautisko nepatentēto nosaukumu):

abacavir hydrochloride monohydrate,Lamivudine

Zāļu forma:

Tablet, film coated

Kompozīcija:

Excipient Ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; ferric oxide; titanium dioxide; hypromellose; sunset yellow FCF; polysorbate 80; macrogol 400

Ievadīšanas:

Oral

Vienības iepakojumā:

30 tablets (opaque white PVC/PVDC Al blister pack)

Receptes veids:

(S4) Prescription Only Medicine

Ārstēšanas norādes:

ABACAVIR/LAMIVUDINE LAPL is a combination of two nucleoside analogues (abacavir and lamivudine). ABACAVIR/LAMIVUDINE LAPL is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and adolescents from 12 years of age.

Produktu pārskats:

Visual Identification: Orange coloured, modified capsule shaped, biconvex, film-coated tablets debossed with 300 on one side and 600 on the other side.; Container Type: Blister Pack; Container Material: PVC/PVDC; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius

Autorizācija statuss:

Licence status A

Autorizācija datums:

2017-10-06